Tim Anderson
Stock Analyst at B of A Securities
(3.71)
# 617
Out of 5,090 analysts
45
Total ratings
58.33%
Success rate
8.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $718.36 | -12.72% | 3 | Oct 29, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $198 → $204 | $201.93 | +1.03% | 8 | Oct 15, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $26.03 | +15.25% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $329.89 | -17.55% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $76.75 | +13.36% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $13.56 | +84.37% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $226.08 | -9.77% | 7 | Apr 28, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $121.22 | +3.94% | 3 | Mar 5, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $27.70 | +22.74% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $99.72 | +12.31% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $52.15 | +20.81% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $181.30 | -1.82% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $1,010.31 | -1.32% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $132.16 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $90.18 | - | 1 | Sep 22, 2017 |
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $718.36
Upside: -12.72%
Johnson & Johnson
Oct 15, 2025
Maintains: Neutral
Price Target: $198 → $204
Current: $201.93
Upside: +1.03%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $26.03
Upside: +15.25%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $329.89
Upside: -17.55%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $76.75
Upside: +13.36%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $13.56
Upside: +84.37%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $226.08
Upside: -9.77%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $121.22
Upside: +3.94%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $27.70
Upside: +22.74%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $99.72
Upside: +12.31%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $52.15
Upside: +20.81%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $181.30
Upside: -1.82%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $1,010.31
Upside: -1.32%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $132.16
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $90.18
Upside: -